Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection

Annapaola Callegaro, Daniela Borleri, Claudio Farina, Gavino Napolitano, Daniela Valenti, Marco Rizzi, Franco Maggiolo
doi: https://doi.org/10.1101/2021.03.09.21253203
Annapaola Callegaro
1Microbiology and Virology Laboratory ASST Papa Giovanni XXIII, Bergamo, Italy
2Biobank ASST Papa Giovanni XXIII, Bergamo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Borleri
3Occupational Medicine Unit ASST Papa Giovanni XXIII, Bergamo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudio Farina
1Microbiology and Virology Laboratory ASST Papa Giovanni XXIII, Bergamo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gavino Napolitano
1Microbiology and Virology Laboratory ASST Papa Giovanni XXIII, Bergamo, Italy
2Biobank ASST Papa Giovanni XXIII, Bergamo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Valenti
4,5FROM Foundation ASST Papa Giovanni XXIII, Bergamo, Italy
5Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Rizzi
5Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Franco Maggiolo
5Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The SARS-CoV-2 pandemic calls for rapid actions, now principally oriented to a world-wide vaccination campaign.

In this study we verified if, in individuals with a previous SARS-CoV-2 infection, a single dose of mRNA vaccine would be immunologically equivalent to a full vaccine schedule in naïve individuals.

Methods Health care workers (184) with a previous SARS-CoV-2 infection were sampled soon before the second dose of vaccine and between 7 and 10 days after the second dose, the last sampling time was applied to SARS-CoV-2 naïve individuals, too.

Antibodies against SARS-CoV-2 were measured using Elecsys® Anti-SARS-CoV-2 S immunoassay.

The study was powered for non-inferiority. We used non parametric tests and Pearson correlation test to perform inferential analysis.

Results After a single vaccine injection, the median titer of specific antibodies in individuals with previous COVID-19 was 30,527 U/ml (IQR 19,992-39,288) and in subjects with previous SARS-CoV-2 asymptomatic infection was 19,367.5 U/ml (IQR 14,688-31,353) (P=0.032). Both results were far above the median titer in naïve individuals after a full vaccination schedule: 1,974.5 U/ml (IQR 895-3,455) (P<0.0001). Adverse events after vaccine injection were more frequent after the second dose of vaccine (mean 0.95, 95%CI from 0.75 to 1.14 versus mean 1.91, 95%CI from 1.63 to 2.19)(P<0.0001) and in exposed compared to naïve (mean 1.63; 95%CI from 1.28 to 1.98 versus mean 2.35; 95%CI from 1.87 to 2.82)(P=0.015).

Conclusion In SARS-CoV-2 naturally infected individuals a single mRNA vaccine dose seems sufficient to reach immunity. Modifying current dosing schedules would speed-up vaccination campaigns.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The study has no funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Provincial Ethical Committee of Bergamo approved the study ruling number 178/01.02.2021

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data are available in an electronic database on request to the principal investigator

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 11, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection
Annapaola Callegaro, Daniela Borleri, Claudio Farina, Gavino Napolitano, Daniela Valenti, Marco Rizzi, Franco Maggiolo
medRxiv 2021.03.09.21253203; doi: https://doi.org/10.1101/2021.03.09.21253203
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection
Annapaola Callegaro, Daniela Borleri, Claudio Farina, Gavino Napolitano, Daniela Valenti, Marco Rizzi, Franco Maggiolo
medRxiv 2021.03.09.21253203; doi: https://doi.org/10.1101/2021.03.09.21253203

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (419)
  • Anesthesia (97)
  • Cardiovascular Medicine (894)
  • Dentistry and Oral Medicine (166)
  • Dermatology (101)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (404)
  • Epidemiology (8744)
  • Forensic Medicine (4)
  • Gastroenterology (403)
  • Genetic and Genomic Medicine (1844)
  • Geriatric Medicine (175)
  • Health Economics (386)
  • Health Informatics (1281)
  • Health Policy (642)
  • Health Systems and Quality Improvement (488)
  • Hematology (206)
  • HIV/AIDS (387)
  • Infectious Diseases (except HIV/AIDS) (10519)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (216)
  • Neurology (1744)
  • Nursing (100)
  • Nutrition (264)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (457)
  • Oncology (959)
  • Ophthalmology (279)
  • Orthopedics (107)
  • Otolaryngology (174)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (262)
  • Pediatrics (553)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1836)
  • Public and Global Health (3962)
  • Radiology and Imaging (649)
  • Rehabilitation Medicine and Physical Therapy (340)
  • Respiratory Medicine (532)
  • Rheumatology (214)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (165)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (105)
  • Urology (78)